SCHEMBL4434635

SCHEMBL4434635

N#Cc1cc(N)cc(N2CCOCC2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 2/20 0.45
NSD2 O96028 1/20 0.45
TSHR P16473 1/20 0.45
CASP1 P29466 1/20 0.45
HTT P42858 1/20 0.45
CASP7 P55210 1/20 0.45
CASP6 P55212 1/20 0.45
AKT1 P31749 3/20 0.44
PIK3CA P42336 3/20 0.44
MTOR P42345 3/20 0.44
LGMN Q99538 2/20 0.42
MAPK1 P28482 1/20 0.41
AR P10275 1/20 0.40
CTSK P43235 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31703324 1.00 KDM4E (0.45) KDM4EMAPTSMN1; SMN2LMNANSD2
SCHEMBL4725669 0.88 KDM4E (0.51) KDM4EMAPTSMN1; SMN2LMNANSD2
SCHEMBL4781715 0.83 ALDH1A1 (0.44) KDM4EMAPTLMNAHTTMAPK1
SCHEMBL1172028 0.82 LGMN (0.53) KDM4EMAPTSMN1; SMN2LMNAHTT
SCHEMBL2712064 0.82 LGMN (0.53) KDM4EMAPTSMN1; SMN2LMNAHTT
SCHEMBL4757023 0.80 LMNA (0.49) KDM4EMAPTSMN1; SMN2LMNANSD2
SCHEMBL3760756 0.80 KDM4E (0.45) KDM4EMAPTSMN1; SMN2LMNANSD2
SCHEMBL4758228 0.80 MAPK1 (0.47) KDM4EMAPTSMN1; SMN2LMNANSD2
SCHEMBL31703179 0.80 MAPK1 (0.47) KDM4EMAPTSMN1; SMN2LMNANSD2
SCHEMBL594313 0.80 KDM4E (0.49) KDM4EMAPTSMN1; SMN2LMNANSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025215121-A1 HEDGEHOG ACYLTRANSFERASE INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2025-10-16 WO disclosed
EP-2132184-A1 NOVEL PYRIMIDINE DERIVATIVES 698 AstraZeneca AB (SE) 2009-12-16 EP disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
WO-2008104754-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-09-04 WO disclosed
WO-2008104754-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-09-04 WO disclosed
WO-2008089034-A2 CYTOKINE INHIBITORS KEMIA, INC. (US) 2008-07-24 WO disclosed
WO-2008021388-A1 HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS KEMIA, INC. (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 EPHB4, EPHB1, NME2 KDM4E 1632/4885MAPT 3593/4885SMN1; SMN2 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.